Esp4 Inhibitors
Esp4 inhibitors are a specialized class of chemical compounds designed to target and inhibit the activity of the Esp4 protein, a key player in various cellular processes. The Esp4 protein is typically involved in specific biochemical pathways or structural roles within the cell, where its function is essential for the regulation and maintenance of these processes. Inhibitors of Esp4 work by binding to the protein, thereby preventing it from carrying out its normal function. This binding can be achieved through several mechanisms, such as direct competition with the natural substrates of Esp4 for its active site, or through allosteric inhibition, where the inhibitor binds to a different region of the protein, causing conformational changes that reduce its activity. The development of Esp4 inhibitors often requires a thorough understanding of the protein's structure and function, employing techniques like X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling to identify and optimize molecules that can effectively inhibit Esp4.
The chemical structures of Esp4 inhibitors are varied, reflecting the diverse strategies used to achieve selective inhibition of this protein. These inhibitors may be small molecules with specific functional groups designed to interact with key residues in the Esp4 protein, or they may be larger, more complex molecules that rely on precise molecular docking to interfere with the protein's function. The design process typically involves structure-activity relationship (SAR) studies, where researchers modify the chemical structure of potential inhibitors and assess their impact on Esp4 activity. This iterative process helps identify the molecular features that are crucial for effective inhibition, such as the arrangement of hydrophobic and hydrophilic regions, the presence of specific binding moieties, and the overall molecular geometry. Additionally, the development of Esp4 inhibitors requires an understanding of the protein's dynamics, including its conformational flexibility and interactions with other cellular components. By refining these molecular interactions, researchers aim to create inhibitors that can modulate Esp4 activity with high specificity and potency, providing valuable insights into the cellular mechanisms in which this protein is involved.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of transforming growth factor-beta (TGF-β) type I receptor. Inhibition of TGF-β signaling may activate Esp4 by preventing its regulation through TGF-β pathways, influencing downstream cellular processes associated with TGF-β, and contributing to Esp4 activation. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin is a DNA cross-linking agent. Esp4 may be inhibited by Cisplatin through interference with DNA-binding activities or downstream signaling, preventing normal cellular processes associated with Esp4 activity. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941 is a selective inhibitor of phosphoinositide 3-kinase (PI3K). Inhibition of PI3K may activate Esp4 by preventing its phosphorylation and modulating downstream signaling pathways. This influence on intracellular signaling cascades can contribute to Esp4 activation. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 is a selective inhibitor of AKT kinase. Inhibition of AKT may activate Esp4 by preventing its phosphorylation and modulating downstream signaling pathways. This impact on intracellular signaling cascades can contribute to Esp4 activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. Esp4 may be inhibited by Rapamycin through modulation of mTOR signaling, preventing its regulation and influencing downstream cellular processes associated with mTOR. This modulation can contribute to Esp4 activation. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV939 is a tankyrase inhibitor. Inhibition of tankyrase may activate Esp4 by preventing its regulation through tankyrase-dependent pathways, influencing downstream cellular processes associated with Esp4, and contributing to Esp4 activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor. Esp4 may be inhibited by Wortmannin through interference with PI3K-dependent signaling, preventing its phosphorylation and modulating downstream pathways. This influence on intracellular signaling cascades can contribute to Esp4 activation. | ||||||
CCT196969 | 1163719-56-9 | sc-507303 | 5 mg | $135.00 | ||
CCT196969 is a selective inhibitor of DNA-PK. Esp4 may be inhibited by CCT196969 through interference with DNA repair mechanisms or other DNA-PK-dependent pathways, preventing normal cellular processes associated with Esp4 activity. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a selective inhibitor of Cdc42. Esp4 may be activated by ML141 through modulation of Cdc42-dependent signaling, influencing downstream cellular processes associated with Esp4 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. Inhibition of PI3K may activate Esp4 by preventing its phosphorylation and modulating downstream signaling pathways. This impact on intracellular signaling cascades can contribute to Esp4 activation. | ||||||